ea0049ep773 | Clinical case reports - Thyroid/Others | ECE2017
Bettencourt-Silva Rita
, Oliveira Joana
, Esteves Cesar
, Hespanhol Venceslau
, Fernandes Gabriela
, Caeiro Claudia
, Queiros Joana
, Carvalho Davide
Background: Nivolumab is a monoclonal antibody specific for human PD-1 (programmed cell death protein-1), a checkpoint molecule highly expressed in several cancers. Nivolumab is an immunotherapeutic strategy for human cancer, but it can interfere with endocrine system.Case reports: We report four cases regarding nivolumab-associated endocrinopathies: (i) Male, 55-year-old, with previous normal cortisol and adrenocorticotropic hormone (ACTH) levels, treat...